Endo International plc
LSE: 0Y5F.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Blaise A. Coleman
- Employees
- 2,931
- Headquarters
- Dublin, Ireland
- IPO year
- 2018
- Market cap
- $99.0K
- Website
- https://www.endo.com
Loading 0Y5F…
Loading profile data…Frequently asked questions about 0Y5F
What does Endo International plc (0Y5F.L) do?
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocio...
Where does 0Y5F.L trade?
Endo International plc (0Y5F.L) trades on the London Stock Exchange.
What sector is 0Y5F.L in?
Endo International plc (0Y5F.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Endo International plc?
Blaise A. Coleman is the chief executive officer of Endo International plc (0Y5F.L).
Where is Endo International plc headquartered?
Endo International plc is headquartered in Ireland.
Does 0Y5F.L pay a dividend?
Endo International plc (0Y5F.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0Y5F.L go public?
Endo International plc (0Y5F.L) completed its initial public offering in 2018.